CXCR1 and neoplasm: The tumor weight at the terminal point of the experiment confirmed the tumor curve, showing that CXCL8-CXCR1/2 blockage limit the weight of SHP2 overexpressing PC9GR tumors than those treated with DMSO, from 2.050 ± 0.184 g to 0.850 ± 0.023 g (Danirixin) and 0.993 ± 0.070 g (Reparixin), and the weight of SHP2 knock-down PC9GR tumors reduced from 1.576 ± 0.116 g to 0.510 ± 0.106 g (Danirixin) and 0.474 ± 0.055 g (Reparixin) (Fig. 6D).